Biomarkers of neurodegeneration in isolated and antidepressant‐related rapid eye movement sleep behavior disorder
European Journal of Neurology · 2024
DOI: 10.1111/ene.16260 ↗At a glance
Beobachtungsstudie in European Journal of Neurology, 2024. Written by Francesco Biscarini and 8 co-authors. Institution: Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Major MEDLINE topics: REM Sleep Behavior Disorder, Antidepressive Agents, Biomarkers, Tomography, Emission-Computed, Single-Photon. Cited 14 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ministero della Salute.
Abstract (original language)
Background and purpose This study compared the features of isolated rapid eye movement (REM) sleep behavior disorder (iRBD) and antidepressant‐related REM sleep behaviour disorder (RBD) with the aim of highlighting markers that might distinguish the two entities.
Methods
The observational cohort study included RBD patients with and without antidepressant use (antiD+ and antiD− patients, respectively), without cognitive impairment and parkinsonism. Clinical features of RBD, subtle motor and non‐motor symptoms of parkinsonism, sleep architecture, REM atonia index, dopamine transporter‐single photon emission computed tomography (DAT‐SPECT) and skin biopsies for the intraneuronal alpha‐synuclein (α‐syn), were evaluated in the baseline work‐up.
Results
Thirty‐nine patients, 10 antiD+ and 29 antiD−, were included. AntiD+ patients (more frequently female) reported more psychiatric symptoms, less violent dream enactment, and less frequent hyposmia. Dermal α‐syn was detected in 93.1% of antiD− versus 30% of antiD+ patients ( p = 0.00024). No differences appeared in other motor and non‐motor symptoms, Movement Disorder Society–Unified Parkinson's Disease Rating Scale part III score, DAT‐SPECT, or polysomnographic features.
Conclusions
Patients with antidepressant‐related RBD have clinical and neuropathological features suggesting a lower risk of evolution than those with iRBD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
- DIMI Department of Engineering and Medicine of Innovation, University of Verona, Verona, Italy.
- Department of Neurology IC, Oasi Research Institute-IRCCS, Troina, Italy.
- Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
ORCID profiles: Francesco Biscarini, Vincenzo Donadio, Raffaele Ferri, Rocco Liguori
Funding
- Ministero della Salute
Cite
APA
Biscarini, F., Pizza, F., Vandi, S., Incensi, A., Antelmi, E., Donadio, V., Ferri, R., Liguori, R., & Plazzi, G. (2024). Biomarkers of neurodegeneration in isolated and antidepressant‐related rapid eye movement sleep behavior disorder. European Journal of Neurology. https://doi.org/10.1111/ene.16260
Vancouver
Biscarini F, Pizza F, Vandi S, Incensi A, Antelmi E, Donadio V, et al. Biomarkers of neurodegeneration in isolated and antidepressant‐related rapid eye movement sleep behavior disorder. European Journal of Neurology. 2024. doi:10.1111/ene.16260
BibTeX
@article{Biscarini2024,
author = {Biscarini, Francesco and Pizza, Fabio and Vandi, Stefano and Incensi, Alex and Antelmi, Elena and Donadio, Vincenzo and Ferri, Raffaele and Liguori, Rocco and Plazzi, Giuseppe},
title = {Biomarkers of neurodegeneration in isolated and antidepressant‐related rapid eye movement sleep behavior disorder},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16260}
}
EUVIMED